BioZorb is an implantable marker made of six titanium clips, which are intended to remain in the body. This device is primarily used to improve outcomes following surgery for breast cancer and ductal carcinoma in situ (DCIS), which is considered the earliest form of breast cancer.
After a surgical procedure such as a lumpectomy, BioZorb is placed inside the breast to help show where future radiation treatment should be targeted. As a result, doctors and surgeons can reduce the volume of radiation needed for postoperative therapies.
Hologic claimed that the device dissolves within the patient’s body within 12 months after the implant. However, the implant often does not dissolve at all, leading to severe complications. Some breast cancer patients are reporting extreme pain, discomfort, and many other side effects due to BioZorb devices.